Skin biopsies from patients with advanced CTCL were evaluated pre- and post-treatment with the anti-PD1 immune checkpoint inhibitor (ICI), pembrolizumab [81]. The gene discussed is PDCD1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.